Published in Atherosclerosis on September 01, 2006
Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm (2006) 2.81
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol (2006) 2.70
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
Statins and the vascular endothelial inflammatory response. Trends Immunol (2007) 1.43
Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med (2009) 1.38
Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respir Viruses (2009) 1.26
Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol (2010) 1.07
Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol (2009) 1.04
Targeting GGTase-I activates RHOA, increases macrophage reverse cholesterol transport, and reduces atherosclerosis in mice. Circulation (2013) 1.01
Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol (2008) 0.97
Hypercholesterolemia links hematopoiesis with atherosclerosis. Trends Endocrinol Metab (2012) 0.94
Disparate effects of simvastatin on angiogenesis during hypoxia and inflammation. Life Sci (2008) 0.92
Functional alterations of myeloid cell subsets in hyperlipidaemia: relevance for atherosclerosis. J Cell Mol Med (2009) 0.91
Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br J Pharmacol (2008) 0.89
Therapeutic strategies to deplete macrophages in atherosclerotic plaques. Br J Clin Pharmacol (2012) 0.88
Cdc42 GTPases facilitate TNF-α-mediated secretion of CCL2 from peripheral nerve microvascular endoneurial endothelial cells. J Peripher Nerv Syst (2013) 0.85
Maintenance of radiation-induced intestinal fibrosis: cellular and molecular features. World J Gastroenterol (2007) 0.84
Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice. Int J Nanomedicine (2016) 0.83
Rho-GTPase and Atherosclerosis: Pleiotropic Effects of Statins. J Am Heart Assoc (2015) 0.83
Statins and vein graft failure in coronary bypass surgery. Curr Opin Pharmacol (2012) 0.81
Antithrombotic actions of statins involve PECAM-1 signaling. Blood (2013) 0.80
Regulation of atherogenesis by chemokines and chemokine receptors. Arch Immunol Ther Exp (Warsz) (2012) 0.80
Antiapoptotic effect of simvastatin ameliorates myocardial ischemia/reperfusion injury. ISRN Pharmacol (2013) 0.79
In vivo transmigrated monocytes from patients with stable coronary artery disease have a reduced expression of CD11b. Clin Exp Immunol (2008) 0.79
Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia. Lipids Health Dis (2014) 0.79
Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders. J Neurovirol (2016) 0.78
Novel role of Cdc42 and RalA GTPases in TNF-α mediated secretion of CCL2. Small GTPases (2014) 0.77
Immunological aspects of atherosclerosis. Semin Immunopathol (2013) 0.77
Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease. J Neuroimmunol (2012) 0.76
PET/CT Imaging of Chemokine Receptors in Inflammatory Atherosclerosis Using Targeted Nanoparticles. J Nucl Med (2016) 0.76
In vivo imaging of leukocyte recruitment to the atheroprone femoral artery reveals anti-inflammatory effects of rosuvastatin. Biomed Res Int (2012) 0.76
Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications. J Diabetes Investig (2012) 0.75
Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis. Br J Pharmacol (2015) 0.75
Management and Prevention of Saphenous Vein Graft Failure: A Review. Cardiol Ther (2017) 0.75
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature (2005) 3.02
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods (2004) 2.84
[Statin treatment in primary and secondary prevention--a statement]. Rev Med Suisse (2014) 2.55
Inferior vena cava parameters predict re-admission in ischaemic heart failure. Eur J Clin Invest (2014) 2.01
Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2006) 1.99
Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res (2003) 1.99
Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation (2004) 1.90
HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS (2009) 1.88
The specific role of chemokines in atherosclerosis. Thromb Haemost (2007) 1.62
Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation (2012) 1.57
Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res (2005) 1.49
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol (2005) 1.49
Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost (2011) 1.48
Late cardiac tamponade after percutaneous closure of a patent foramen ovale. Eur J Echocardiogr (2005) 1.41
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation (2009) 1.41
Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation (2005) 1.40
Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic intervention. Eur J Cardiovasc Prev Rehabil (2010) 1.33
Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.32
Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation (2006) 1.31
A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol (2008) 1.30
CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol (2008) 1.25
CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol (2009) 1.24
The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol (2009) 1.24
Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation (2003) 1.22
Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med (2005) 1.22
Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2002) 1.21
A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Hum Mutat (2008) 1.21
Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol (2009) 1.20
Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease. ILAR J (2009) 1.16
Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways. Cell Signal (2007) 1.16
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene (2005) 1.15
The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost (2009) 1.14
CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost (2010) 1.13
Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy. Arthritis Rheum (2006) 1.13
Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev (2003) 1.12
Reduced connexin43 expression limits neointima formation after balloon distension injury in hypercholesterolemic mice. Circulation (2006) 1.11
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res (2003) 1.07
PARP1 is required for adhesion molecule expression in atherogenesis. Cardiovasc Res (2007) 1.06
The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm (2009) 1.05
Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J (2011) 1.05
Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol (2009) 1.04
Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal (2012) 1.04
Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail (2011) 1.03
Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. Circ Res (2008) 1.02
Obstructive sleep apnea and atherosclerosis. Prog Cardiovasc Dis (2009) 1.01
Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke (2010) 1.00
Toll-like receptor 7 protects from atherosclerosis by constraining "inflammatory" macrophage activation. Circulation (2012) 0.99
In vivo labelling of resting monocytes in the reticuloendothelial system with fluorescent iron oxide nanoparticles prior to injury reveals that they are mobilized to infarcted myocardium. Eur Heart J (2009) 0.99
Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm (2008) 0.99